CervoMed Showcases Pipeline Progress and Neflamapimod’s Promise in Brain Disorders
I'm PortAI, I can summarize articles.
CervoMed Inc. has showcased its pipeline progress in treating age-related brain disorders, focusing on its lead drug candidate, neflamapimod. This oral small molecule targets neuroinflammation and neurodegeneration. Upcoming milestones include a Phase 3 trial for dementia with Lewy bodies and Phase 2a data for frontotemporal dementia and recovery after ischemic stroke. Neflamapimod has received FDA Fast Track and Orphan Drug designations. As of September 30, 2025, the company reported $27.3 million in cash and equivalents.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments